Epidermal growth factor regulates Mcl-1 expression through the MAPK-Elk-1 signalling pathway contributing to cell survival in breast cancer

Oncogene

Volumn 30, Issue 20, 2011, Pages 2367-2378

  Booy, E P ^a,b   Henson, E S ^a,b   Gibson, S B ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

breast cancer; drug resistance; Elk 1; Mcl 1; regulation

Indexed keywords

BIOTIN; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN BCL 2; PROTEIN MCL 1; SERUM RESPONSE FACTOR; TRANSCRIPTION FACTOR ELK 1; TUBULIN;

APOPTOSIS; ARTICLE; BINDING SITE; BREAST CANCER; CANCER GRADING; CANCER PATIENT; CANCER SURVIVAL; CELL PROLIFERATION; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; UPREGULATION;

APOPTOSIS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; EPIDERMAL GROWTH FACTOR; ETS-DOMAIN PROTEIN ELK-1; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-BCL-2; RNA, MESSENGER; SERUM RESPONSE ELEMENT; SIGNAL TRANSDUCTION;

EID: 79956113945     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.616     Document Type: Article

References (57)

1. Akgul C, Turner PC, White MR, Edwards SW. (2000). Functional analysis of the human Mcl-1 gene. Cell Mol Life Sci 57: 684-691. (Pubitemid 30311437)
2. Akgul C. (2009). Mcl-1 is a potential therapeutic target in multiple types of cancer. Cell Mol Life Sci 66: 1326-1336.
3. Backus HH, Van Riel JM, Van Groeningen CJ, Vos W, Dukers DF, Bloemena E et al. (2001). Rb, mcl-1 and p53 expression correlate with clinical outcome in patients with liver metastases from colorectal cancer. Ann Oncol 12: 779-785. (Pubitemid 32655086)
4. Bingle CD, Craig RW, Swales BM, Singleton V, Zhou P, Whyte MK. (2000). Exon skipping in Mcl-1 results in a bcl-2 homology domain 3 only gene product that promotes cell death. J Biol Chem 275: 22136-22146. (Pubitemid 30621794)
5. Boros J, O'Donnell A, Donaldson IJ, Kasza A, Zeef L, Sharrocks AD. (2009). Overlapping promoter targeting by Elk-1 and other divergent ETS-domain transcription factor family members. Nucleic Acids Res 37: 7368-7380.
6. Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J, Rivard N. (2000). MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem 79: 355-369.
7. Cetin Z, Ozbilim G, Erdogan A, Luleci G, Karauzum SB. (2010). Evaluation of PTEN and Mcl-1 expressions in NSCLC expressing wild-type or mutated EGFR. Med Oncol 27: 853-860.
8. Chen F, Hancock CN, Macias AT, Joh J, Still K, Zhong S et al. (2006). Characterization of ATP-independent ERK inhibitors identified through in silico analysis of the active ERK2 structure. Bioorg Med Chem Lett 16: 6281-6287. (Pubitemid 44712061)
9. Chrysogelos SA, Dickson RB. (1994). EGF receptor expression, regulation, and function in breast cancer. Breast Cancer Res Treat 29: 29-40. (Pubitemid 24104835)
10. Ding Q, He X, Xia W, Hsu JM, Chen CT, Li LY et al. (2007). Myeloid cell leukemia-1 inversely correlates with glycogen synthase kinase-3beta activity and associates with poor prognosis in human breast cancer. Cancer Res 67: 4564-4571. (Pubitemid 46910160)
11. Favata MF, Horiuchi KY, Manos EJ, Daulerio AJ, Stradley DA, Feeser WS et al. (1998). Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J Biol Chem 273: 18623-18632. (Pubitemid 28334795)
12. Heinemeyer T, Wingender E, Reuter I, Hermjakob H, Kel AE, Kel OV et al. (1998). Databases on transcriptional regulation: TRANSFAC, TRRD and COMPEL. Nucleic Acids Res 26: 362-367. (Pubitemid 28295292)
13. Henson ES, Hu X, Gibson SB. (2006). Herceptin sensitizes ErbB2-overexpressing cells to apoptosis by reducing antiapoptotic Mcl-1 expression. Clin Cancer Res 12: 845-853. (Pubitemid 43259867)
14. Herbst RS. (2004). Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 59: 21-26. (Pubitemid 38610223)
15. Hoeflich KP, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K et al. (2009). In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 15: 4649-4664.
16. Hsieh FC, Cheng G, Lin J. (2005). Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem Biophys Res Commun 335: 292-299. (Pubitemid 41140220)
17. Johnston JB, Navaratnam S, Pitz MW, Maniate JM, Wiechec E, Baust H et al. (2006). Targeting the EGFR pathway for cancer therapy. Curr Med Chem 13: 3483-3492. (Pubitemid 44873742)
18. Klapper LN, Kirschbaum MH, Sela M, Yarden Y. (2000). Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. Adv Cancer Res 77: 25-79. (Pubitemid 29439302)
19. Kuo ML, Chuang SE, Lin MT, Yang SY. (2001). The involvement of PI 3-K/Akt-dependent up-regulation of Mcl-1 in the prevention of apoptosis of Hep3B cells by interleukin-6. Oncogene 20: 677-685.
20. Le Gouill S, Podar K, Harousseau JL, Anderson KC. (2004). Mcl-1 regulation and its role in multiple myeloma. Cell Cycle 3: 1259-1262. (Pubitemid 40268607)
21. Leu CM, Chang C, Hu C. (2000). Epidermal growth factor (EGF) suppresses staurosporine-induced apoptosis by inducing mcl-1 via the mitogen-activated protein kinase pathway. Oncogene 19: 1665-1675. (Pubitemid 30200968)
22. Lin X, Morgan-Lappe S, Huang X, Li L, Zakula DM, Vernetti LA et al. (2007). 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. Oncogene 26: 3972-3979. (Pubitemid 46884293)
23. Liu H, Ma Y, Cole SM, Zander C, Chen KH, Karras J et al. (2003). Serine phosphorylation of STAT3 is essential for Mcl-1 expression and macrophage survival. Blood 102: 344-352. (Pubitemid 36759675)
24. Longo PG, Laurenti L, Gobessi S, Sica S, Leone G, Efremov DG. (2008). The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 111: 846-855.
25. Martin AP, Mitchell C, Rahmani M, Nephew KP, Grant S, Dent P. (2009). Inhibition of MCL-1 enhances lapatinib toxicity and overcomes lapatinib resistance via BAK-dependent autophagy. Cancer Biol Ther 8: 2084-2096.
26. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R et al. (2009). Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 69: 565-572.
27. Mott JL, Kobayashi S, Bronk SF, Gores GJ. (2007). mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 26: 6133-6140. (Pubitemid 47414372)
28. Mueller H, Flury N, Eppenberger-Castori S, Kueng W, David F, Eppenberger U. (2000). Potential prognostic value of mitogen-activated protein kinase activity for disease-free survival of primary breast cancer patients. Int J Cancer 89: 384-388. (Pubitemid 30620293)
29. Nahta R, Esteva FJ. (2006). HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8: 215.
30. Nanda R. (2007). Targeting the human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer: recent advances and future directions. Rev Recent Clin Trials 2: 111-116. (Pubitemid 46773878)
31. Nguyen M, Marcellus RC, Roulston A, Watson M, Serfass L, Murthy Madiraju SR et al. (2007). Small molecule obatoclax (GX15-070) antagonizes MCL-1 and overcomes MCL-1-mediated resistance to apoptosis. Proc Natl Acad Sci USA 104: 19512-19517.
32. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. (2005). An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 435: 677-681. (Pubitemid 40825512)
33. Puthier D, Bataille R, Amiot M. (1999). IL-6 up-regulates mcl-1 in human myeloma cells through JAK/STAT rather than ras/MAP kinase pathway. Eur J Immunol 29: 3945-3950.
34. Riccardi C, Nicoletti I. (2006). Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 1: 1458-1461.
35. Sambade MJ, Camp JT, Kimple RJ, Sartor CI, Shields JM. (2009). Mechanism of lapatinib-mediated radiosensitization of breast cancer cells is primarily by inhibition of the Raf4MEK4ERK mitogen-activated protein kinase cascade and radiosensitization of lapatinib-resistant cells restored by direct inhibition of MEK. Radiother Oncol 93: 639-644.
36. Schubert KM, Duronio V. (2001). Distinct roles for extracellular-signal- regulated protein kinase (ERK) mitogen-activated protein kinases and phosphatidylinositol 3-kinase in the regulation of Mcl-1 synthesis. Biochem J 356: 473-480. (Pubitemid 32532358)
37. Schulze-Bergkamen H, Ehrenberg R, Hickmann L, Vick B, Urbanik T, Schimanski CC et al. (2008). Bcl-x(L) and myeloid cell leukaemia-1 contribute to apoptosis resistance of colorectal cancer cells. World J Gastroenterol 14: 3829-3840.
38. Singleton TP, Strickler JG. (1992). Clinical and pathologic significance of the c-erbB-2 (HER-2/neu) oncogene. Pathol Annu 27(Part 1): 165-190.
39. Sithanandam G, Anderson LM. (2008). The ERBB3 receptor in cancer and cancer gene therapy. Cancer Gene Ther 15: 413-448. (Pubitemid 351822188)
40. Sivaraman VS, Wang H, Nuovo GJ, Malbon CC. (1997). Hyper-expression of mitogen-activated protein kinase in human breast cancer. J Clin Invest 99: 1478-1483. (Pubitemid 27163797)
41. Skliris GP, Hube F, Gheorghiu I, Mutawe MM, Penner C, Watson PH et al. (2008). Expression of small breast epithelial mucin (SBEM) protein in tissue microarrays (TMAs) of primary invasive breast cancers. Histopathology 52: 355-369. (Pubitemid 351208066)
42. Song L, Coppola D, Livingston S, Cress D, Haura EB. (2005). Mcl-1 regulates survival and sensitivity to diverse apoptotic stimuli in human non-small cell lung cancer cells. Cancer Biol Ther 4: 267-276. (Pubitemid 41351285)
43. Spencer VA, Sun JM, Li L, Davie JR. (2003). Chromatin immuno-precipitation: a tool for studying histone acetylation and transcription factor binding. Methods 31: 67-75. (Pubitemid 36945172)
44. Townsend KJ, Zhou P, Qian L, Bieszczad CK, Lowrey CH, Yen A et al. (1999). Regulation of MCL1 through a serum response factor/ Elk-1-mediated mechanism links expression of a viability-promoting member of the BCL2 family to the induction of hematopoietic cell differentiation. J Biol Chem 274: 1801-1813.
45. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S et al. (2008). ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68: 3421-3428.
46. Tsutsui M, Yasuda H, Suto H, Imai H, Isobe Y, Sasaki M et al. (2009). Frequent STAT3 activation is associated with Mcl-1 expression in nasal NK-cell lymphoma. Int J Lab Hematol 32: 419-426.
47. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. (2006). The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/ Bax if Mcl-1 is neutralized. Cancer Cell 10: 389-399. (Pubitemid 44711953)
48. Vickers ER, Kasza A, Kurnaz IA, Seifert A, Zeef LA, O'Donnell A et al. (2004). Ternary complex factor-serum response factor complex-regulated gene activity is required for cellular proliferation and inhibition of apoptotic cell death. Mol Cell Biol 24: 10340-10351. (Pubitemid 39507871)
49. Vogler M, Dinsdale D, Dyer MJ, Cohen GM. (2009). Bcl-2 inhibitors: small molecules with a big impact on cancer therapy. Cell Death Differ 16: 360-367.
50. Von Lintig FC, Dreilinger AD, Varki NM, Wallace AM, Casteel DE, Boss GR. (2000). Ras activation in human breast cancer. Breast Cancer Res Treat 62: 51-62. (Pubitemid 30609563)
51. Wang JM, Chao JR, Chen W, Kuo ML, Yen JJ, Yang-Yen HF. (1999). The antiapoptotic gene mcl-1 is up-regulated by the phosphatidylinositol 3-kinase/Akt signaling pathway through a transcription factor complex containing CREB. Mol Cell Biol 19: 6195-6206. (Pubitemid 29399324)
52. Watson PH, Snell L, Parisien M. (1996). The NCIC-Manitoba Breast Tumor Bank: a resource for applied cancer research. CMAJ 155: 281-283. (Pubitemid 26267999)
53. Witters LM, Witkoski A, Planas-Silva MD, Berger M, Viallet J, Lipton A. (2007). Synergistic inhibition of breast cancer cell lines with a dual inhibitor of EGFR-HER-2/neu and a Bcl-2 inhibitor. Oncol Rep 17: 465-469.
54. Yip KW, Reed JC. (2008). Bcl-2 family proteins and cancer. Oncogene 27: 6398-6406.
55. Yordy JS, Muise-Helmericks RC. (2000). Signal transduction and the Ets family of transcription factors. Oncogene 19: 6503-6513. (Pubitemid 32108440)
56. Zhang B, Gojo I, Fenton RG (2002). Myeloid cell factor-1 is a critical survival factor for multiple myeloma. Blood 99: 1885-1893. (Pubitemid 34525465)
57. Zoppoli G, Moran E, Soncini D, Cea M, Garuti A, Rocco I et al. (2010). Ras-induced resistance to lapatinib is overcome by MEK inhibition. Curr Cancer Drug Targets 10: 168-175.